EZH2 and cancer: In the context of cancer, there is chronic antigen stimulation where such phenotypes as SLEC and MPEC may no longer be applicable, making the comparison to acute pathogenic infection more complicated in defining the CD8+ T cell subpopulations affected by EZH2 inhibition.